Research improves understanding of how gut bacteria affect hypertension

ddf8d0b7-1c32-4013-83ae-ad646b939d62articleimage.jpg

05 Oct 2017 --- Scientists are a step closer to identifying a mechanism to explain how gut bacteria increase blood pressure, thanks to US researchers from the University of Illinois (U of I) and Brown University. Jason Ridlon, an assistant professor in the Department of Animal Sciences at U of I, first discovered the gene for an enzyme in certain bacteria that changes cortisol, a steroid hormone, into another steroid known as an androgen.

Ridlon worked with endocrinologist David Morris at Brown and found that when bacteria break that androgen down further, the end product, a molecule called a GALF, disrupts a process that regulates sodium transport out of human kidney cells. When that happens, sodium builds up in cells, and blood pressure rises.

The news comes at a time when one in three American adults suffers from high blood pressure, or hypertension, notes the University of Illinois College of Agricultural, Consumer and Environmental Sciences (ACES) press release. The disease can be passed down in families, and certain lifestyle factors such as smoking, high-sodium diets, and stress can increase the risk.

In recent years, scientists have discovered that certain gut bacteria may contribute to hypertension as well. In a few studies, when gut bacteria were killed off with antibiotics, patients with hypertension saw a drop in blood pressure. In addition, when gut bacteria were transplanted from hypertensive people into normal mice, they developed high blood pressure.

“There are probably multiple mechanisms through which gut bacteria can affect hypertension, but this is one that needs to be pursued,” Ridlon says. He and Morris explore the idea in depth in a new article published in the journal Steroids.

Fooling the receptor
To maintain normal blood pressure, a particular receptor has to bind with a molecule called aldosterone and then move into the cell nucleus. That sparks a cascade of reactions whose end-product is a protein that manages normal sodium and potassium transport into and out of the cell. But the receptor can be fooled, binding to cortisol instead of aldosterone.

If that happens, as it does in rare inpiduals with a disease called apparent mineralocorticoid excess (AME), the cascade of reactions goes into hyperdrive. Sodium is imported faster than it can be exported, and the cell begins to swell into a dangerous hypertensive state.

In normal inpiduals, an enzyme called 11βHSD2 acts as the guardian of that receptor, keeping cortisol from binding by changing it to cortisone. GALFs – a molecule of which there are a number – stop 11βHSD2 from working. Cortisol floods the receptor binding sites and hypertension starts.

From a different research effort, Ridlon has found that not all gut bacteria metabolize cortisol in the same way, or generate GALFs.

“Two people might have the same amount of the bacterium Clostridium scindens, for example, but one person might have the type that has the pathway for generating these steroids. You can only tell by quantifying the genes, but we have to find them first,” Ridlon says.

In a recent article, published in the Journal of Lipid Research, he does just that, reporting the genes involved in GALF formation in Butyricicoccus desmolans.

“The next step is trying to see if these pathways correlate in patients that have certain forms of hypertension,” Ridlon says. “Are there higher abundances of these genes?”

The hope is that one day the research will lead to a drug therapy to combat hypertension. Ridlon says if they are better able to understand what the bacteria are doing, it would be possible to develop inhibitors of the enzymes that produce GALFs in these bacteria. “It would be great if we could find a targeted solution instead of wiping out everything with antibiotics,” he says.

Ridlon and Morris co-authored “Glucocorticoids and gut bacteria: ‘The GALF Hypothesis’ in the metagenomic era,” published in Steroids. Ridlon, Saravanan Devendran, and Celia Mendez-Garcia co-authored “Identification and characterization of a 20β-HSDH from the anaerobic gut bacterium Butyricicoccus desmolans ATCC 43058,” published in the Journal of Lipid Research.

RELATED ARTICLES
Homepicture

Naturex and Milne partner on Concord grape extract research and commercialization

16 Oct 2017 Naturex’s Open Innovation Program Ingenium ...

Homepicture

Scientists map the neurons driving salt cravings

02 Oct 2017 Researchers have shed new light on how hormones ...

Homepicture

LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

29 Sep 2017 LNC Therapeutics, a company specialized in the ...

Homepicture

ID Nutra’s satiety product gets EFSA novel food nod

28 Sep 2017 The thirst and hunger suppressing specimen H. ...

Homepicture

CK Nutraceuticals partners with Kunpoong to distribute chitosan oligosaccharide

28 Sep 2017 South Korea’s Kunpoong Bio Co. Ltd., a ...